What is the clinical impact of staging and surveillance PET‐CT scan findings in patients with bone and soft tissue sarcoma?
Background and Objectives Positron emission tomography‐computerized tomography (PET‐CTs) are becoming increasingly utilized in sarcoma care, workup, and surveillance. This study aimed to describe additional PET‐CT findings as well as subsequent workups and changes in the clinical course due to those...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2022-04, Vol.125 (5), p.901-906 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 906 |
|---|---|
| container_issue | 5 |
| container_start_page | 901 |
| container_title | Journal of surgical oncology |
| container_volume | 125 |
| creator | Lee, Linus Kazmer, Alexander Colman, Matthew W. Gitelis, Steven Batus, Marta Blank, Alan T. |
| description | Background and Objectives
Positron emission tomography‐computerized tomography (PET‐CTs) are becoming increasingly utilized in sarcoma care, workup, and surveillance. This study aimed to describe additional PET‐CT findings as well as subsequent workups and changes in the clinical course due to those results.
Methods
Patient records were retrospectively reviewed, and the additional workups and evaluations triggered by PET‐CT findings were qualitatively analyzed to document their results. Additional changes in the clinical course were documented.
Results
A total of 183 bone and soft tissue sarcoma patients underwent PET‐CT as part of staging or surveillance. Additional workup was performed in 31.5% (n = 41 of 130) patients who had positive PET‐CT findings. Among these, 36.6% (n = 15 of 41) patients had clinically significant findings that altered the clinical course. Overall, 14.8% (n = 27 of 183) experienced a change in the clinical course due to PET‐CT.
Conclusion
PET‐CT often highlights lesions of potential clinical importance. Additional workup, as well as changes in the clinical course, were not infrequent. Future, multi‐institutional studies should address the value of PET‐CT in sarcoma care. |
| doi_str_mv | 10.1002/jso.26789 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2619541516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2637842486</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-d6d4aa1d9d6a89ef0dba91fd6b2a054e84cf34133386dfe475a91c21d387a2173</originalsourceid><addsrcrecordid>eNp10c1qFTEUB_Agir2tLnwBCbixi2nzNZnJSsqlWqVQwSsuh3Pz0ZvLTHKdZCxdCD6Cz-iTNNdpuxBcZXF-588Jf4ReUXJCCWGn2xRPmGxa9QQtKFGyUkS1T9GizFglGkUO0GFKW0KIUlI8Rwe8JoxT2SzQz28byNgnnDcW694Hr6HHftiBzjg6nDJc-3CNIRicpvGH9X0PQVv8-Xz159fv5QonDQE7H0xhCfuAd5C9DTnhG583eB2Dnbejyzj7lCaLE4w6DvDuBXrmoE_25f17hL6-P18tL6rLqw8fl2eXleY1V5WRRgBQo4yEVllHzBoUdUauGZBa2FZoxwXlnLfSOCuauow1o4a3DTDa8CP0ds7djfH7ZFPuBp-03X_Fxil1TFJVC1pTWeibf-g2TmMo1xXFm1Yw0e7V8az0GFMaret2ox9gvO0o6faddKWT7m8nxb6-T5zWgzWP8qGEAk5ncON7e_v_pO7Tl6s58g6QppcV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637842486</pqid></control><display><type>article</type><title>What is the clinical impact of staging and surveillance PET‐CT scan findings in patients with bone and soft tissue sarcoma?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lee, Linus ; Kazmer, Alexander ; Colman, Matthew W. ; Gitelis, Steven ; Batus, Marta ; Blank, Alan T.</creator><creatorcontrib>Lee, Linus ; Kazmer, Alexander ; Colman, Matthew W. ; Gitelis, Steven ; Batus, Marta ; Blank, Alan T.</creatorcontrib><description>Background and Objectives
Positron emission tomography‐computerized tomography (PET‐CTs) are becoming increasingly utilized in sarcoma care, workup, and surveillance. This study aimed to describe additional PET‐CT findings as well as subsequent workups and changes in the clinical course due to those results.
Methods
Patient records were retrospectively reviewed, and the additional workups and evaluations triggered by PET‐CT findings were qualitatively analyzed to document their results. Additional changes in the clinical course were documented.
Results
A total of 183 bone and soft tissue sarcoma patients underwent PET‐CT as part of staging or surveillance. Additional workup was performed in 31.5% (n = 41 of 130) patients who had positive PET‐CT findings. Among these, 36.6% (n = 15 of 41) patients had clinically significant findings that altered the clinical course. Overall, 14.8% (n = 27 of 183) experienced a change in the clinical course due to PET‐CT.
Conclusion
PET‐CT often highlights lesions of potential clinical importance. Additional workup, as well as changes in the clinical course, were not infrequent. Future, multi‐institutional studies should address the value of PET‐CT in sarcoma care.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.26789</identifier><identifier>PMID: 35023167</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Bone cancer ; Bone Neoplasms - diagnostic imaging ; Bone Neoplasms - pathology ; bone sarcoma ; Fluorodeoxyglucose F18 ; Health surveillance ; Humans ; Neoplasm Staging ; PET‐CT ; Positron Emission Tomography Computed Tomography - methods ; Positron-Emission Tomography ; Radiopharmaceuticals ; Retrospective Studies ; Sarcoma ; Sarcoma - diagnostic imaging ; Sarcoma - pathology ; Sarcoma - therapy ; soft tissue sarcoma ; staging ; surveillance ; Tomography</subject><ispartof>Journal of surgical oncology, 2022-04, Vol.125 (5), p.901-906</ispartof><rights>2022 Wiley Periodicals LLC</rights><rights>2022 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-d6d4aa1d9d6a89ef0dba91fd6b2a054e84cf34133386dfe475a91c21d387a2173</citedby><cites>FETCH-LOGICAL-c3539-d6d4aa1d9d6a89ef0dba91fd6b2a054e84cf34133386dfe475a91c21d387a2173</cites><orcidid>0000-0002-3790-9061 ; 0000-0003-2531-5976</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.26789$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.26789$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35023167$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Linus</creatorcontrib><creatorcontrib>Kazmer, Alexander</creatorcontrib><creatorcontrib>Colman, Matthew W.</creatorcontrib><creatorcontrib>Gitelis, Steven</creatorcontrib><creatorcontrib>Batus, Marta</creatorcontrib><creatorcontrib>Blank, Alan T.</creatorcontrib><title>What is the clinical impact of staging and surveillance PET‐CT scan findings in patients with bone and soft tissue sarcoma?</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Background and Objectives
Positron emission tomography‐computerized tomography (PET‐CTs) are becoming increasingly utilized in sarcoma care, workup, and surveillance. This study aimed to describe additional PET‐CT findings as well as subsequent workups and changes in the clinical course due to those results.
Methods
Patient records were retrospectively reviewed, and the additional workups and evaluations triggered by PET‐CT findings were qualitatively analyzed to document their results. Additional changes in the clinical course were documented.
Results
A total of 183 bone and soft tissue sarcoma patients underwent PET‐CT as part of staging or surveillance. Additional workup was performed in 31.5% (n = 41 of 130) patients who had positive PET‐CT findings. Among these, 36.6% (n = 15 of 41) patients had clinically significant findings that altered the clinical course. Overall, 14.8% (n = 27 of 183) experienced a change in the clinical course due to PET‐CT.
Conclusion
PET‐CT often highlights lesions of potential clinical importance. Additional workup, as well as changes in the clinical course, were not infrequent. Future, multi‐institutional studies should address the value of PET‐CT in sarcoma care.</description><subject>Bone cancer</subject><subject>Bone Neoplasms - diagnostic imaging</subject><subject>Bone Neoplasms - pathology</subject><subject>bone sarcoma</subject><subject>Fluorodeoxyglucose F18</subject><subject>Health surveillance</subject><subject>Humans</subject><subject>Neoplasm Staging</subject><subject>PET‐CT</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Positron-Emission Tomography</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>Sarcoma</subject><subject>Sarcoma - diagnostic imaging</subject><subject>Sarcoma - pathology</subject><subject>Sarcoma - therapy</subject><subject>soft tissue sarcoma</subject><subject>staging</subject><subject>surveillance</subject><subject>Tomography</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10c1qFTEUB_Agir2tLnwBCbixi2nzNZnJSsqlWqVQwSsuh3Pz0ZvLTHKdZCxdCD6Cz-iTNNdpuxBcZXF-588Jf4ReUXJCCWGn2xRPmGxa9QQtKFGyUkS1T9GizFglGkUO0GFKW0KIUlI8Rwe8JoxT2SzQz28byNgnnDcW694Hr6HHftiBzjg6nDJc-3CNIRicpvGH9X0PQVv8-Xz159fv5QonDQE7H0xhCfuAd5C9DTnhG583eB2Dnbejyzj7lCaLE4w6DvDuBXrmoE_25f17hL6-P18tL6rLqw8fl2eXleY1V5WRRgBQo4yEVllHzBoUdUauGZBa2FZoxwXlnLfSOCuauow1o4a3DTDa8CP0ds7djfH7ZFPuBp-03X_Fxil1TFJVC1pTWeibf-g2TmMo1xXFm1Yw0e7V8az0GFMaret2ox9gvO0o6faddKWT7m8nxb6-T5zWgzWP8qGEAk5ncON7e_v_pO7Tl6s58g6QppcV</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Lee, Linus</creator><creator>Kazmer, Alexander</creator><creator>Colman, Matthew W.</creator><creator>Gitelis, Steven</creator><creator>Batus, Marta</creator><creator>Blank, Alan T.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3790-9061</orcidid><orcidid>https://orcid.org/0000-0003-2531-5976</orcidid></search><sort><creationdate>202204</creationdate><title>What is the clinical impact of staging and surveillance PET‐CT scan findings in patients with bone and soft tissue sarcoma?</title><author>Lee, Linus ; Kazmer, Alexander ; Colman, Matthew W. ; Gitelis, Steven ; Batus, Marta ; Blank, Alan T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-d6d4aa1d9d6a89ef0dba91fd6b2a054e84cf34133386dfe475a91c21d387a2173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bone cancer</topic><topic>Bone Neoplasms - diagnostic imaging</topic><topic>Bone Neoplasms - pathology</topic><topic>bone sarcoma</topic><topic>Fluorodeoxyglucose F18</topic><topic>Health surveillance</topic><topic>Humans</topic><topic>Neoplasm Staging</topic><topic>PET‐CT</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Positron-Emission Tomography</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>Sarcoma</topic><topic>Sarcoma - diagnostic imaging</topic><topic>Sarcoma - pathology</topic><topic>Sarcoma - therapy</topic><topic>soft tissue sarcoma</topic><topic>staging</topic><topic>surveillance</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Linus</creatorcontrib><creatorcontrib>Kazmer, Alexander</creatorcontrib><creatorcontrib>Colman, Matthew W.</creatorcontrib><creatorcontrib>Gitelis, Steven</creatorcontrib><creatorcontrib>Batus, Marta</creatorcontrib><creatorcontrib>Blank, Alan T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Linus</au><au>Kazmer, Alexander</au><au>Colman, Matthew W.</au><au>Gitelis, Steven</au><au>Batus, Marta</au><au>Blank, Alan T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What is the clinical impact of staging and surveillance PET‐CT scan findings in patients with bone and soft tissue sarcoma?</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2022-04</date><risdate>2022</risdate><volume>125</volume><issue>5</issue><spage>901</spage><epage>906</epage><pages>901-906</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background and Objectives
Positron emission tomography‐computerized tomography (PET‐CTs) are becoming increasingly utilized in sarcoma care, workup, and surveillance. This study aimed to describe additional PET‐CT findings as well as subsequent workups and changes in the clinical course due to those results.
Methods
Patient records were retrospectively reviewed, and the additional workups and evaluations triggered by PET‐CT findings were qualitatively analyzed to document their results. Additional changes in the clinical course were documented.
Results
A total of 183 bone and soft tissue sarcoma patients underwent PET‐CT as part of staging or surveillance. Additional workup was performed in 31.5% (n = 41 of 130) patients who had positive PET‐CT findings. Among these, 36.6% (n = 15 of 41) patients had clinically significant findings that altered the clinical course. Overall, 14.8% (n = 27 of 183) experienced a change in the clinical course due to PET‐CT.
Conclusion
PET‐CT often highlights lesions of potential clinical importance. Additional workup, as well as changes in the clinical course, were not infrequent. Future, multi‐institutional studies should address the value of PET‐CT in sarcoma care.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35023167</pmid><doi>10.1002/jso.26789</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-3790-9061</orcidid><orcidid>https://orcid.org/0000-0003-2531-5976</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2022-04, Vol.125 (5), p.901-906 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2619541516 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Bone cancer Bone Neoplasms - diagnostic imaging Bone Neoplasms - pathology bone sarcoma Fluorodeoxyglucose F18 Health surveillance Humans Neoplasm Staging PET‐CT Positron Emission Tomography Computed Tomography - methods Positron-Emission Tomography Radiopharmaceuticals Retrospective Studies Sarcoma Sarcoma - diagnostic imaging Sarcoma - pathology Sarcoma - therapy soft tissue sarcoma staging surveillance Tomography |
| title | What is the clinical impact of staging and surveillance PET‐CT scan findings in patients with bone and soft tissue sarcoma? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T10%3A08%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20is%20the%20clinical%20impact%20of%20staging%20and%20surveillance%20PET%E2%80%90CT%20scan%20findings%20in%20patients%20with%20bone%20and%20soft%20tissue%20sarcoma?&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Lee,%20Linus&rft.date=2022-04&rft.volume=125&rft.issue=5&rft.spage=901&rft.epage=906&rft.pages=901-906&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.26789&rft_dat=%3Cproquest_cross%3E2637842486%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637842486&rft_id=info:pmid/35023167&rfr_iscdi=true |